Renal Denervation Therapy in Hypertensive Patients Undergoing A-Fib Ablation

Stopped early · Not applicable

Conditions studied: Atrial Fibrillation, Hypertension

In brief

We propose a pilot study to assess safety and benefit of renal artery ablation at the time of planned atrial fibrillation ablation.

Key facts

Study ID

NCT01952743

Run by

Siva Mulpuru

People needed

3

Starts

2013-09-01

Expected to finish

2015-10-01

Last updated by the study team

2017-03-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Paroxysmal and Persistent Atrial Fibrillation refractory eligible for AF ablation as per HRS/ECAS/EHRA consensus statement.[23] Paroxysmal AF is defined as two or more episodes of AF lasting less than 7 days in duration during the last 6 months before enrollment. Persistent AF is defined as AF lasting more than 7 days or requiring cardioversion for termination.
• Hypertension (>140/80 mm Hg) on treatment with at least 1 hypertensive medication.
• GFR >60ml/dl using Cockcroft- Gault equation

You may not qualify if…

• Secondary causes of hypertension
• Severe renal artery stenosis or dual renal arteries
• Congestive heart failure with NYHA class III or IV status
• EF< 35%
• LA Diameter >6 cm
• Previous AF ablation
• Previous renal artery stent or angioplasty
• Severe contrast allergy
• Inability to give informed consent
• Solitary kidney

Where it is running

• Mayo Clinic — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.